S1E69 - Science Before Hype in MedTech Investing with Varun Turlapati of Chaanakya Capital | Ep 69

Early-stage MedTech gets riskier when investors confuse a compelling story with a credible device. Stronger diligence starts by testing whether the science is real, whether clinicians would actually use the product, and whether the company has thought seriously about regulatory fit, reimbursement logic, and engineering durability.

That framework becomes even more important in neurotech, where public fascination can outrun the evidence base and where the difference between a breakthrough and a weak claim is often diligence quality.

Episode Breakdown

00:00 Opening

02:42 Science and engineering filters

07:55 Why neurotech still...